Literature DB >> 28988525

The role of biofilm forming on mortality in patients with candidemia: a study derived from real world data.

Carlo Tascini1, Emanuela Sozio2, Laura Corte3,4, Francesco Sbrana5, Claudio Scarparo6, Andrea Ripoli4, Giacomo Bertolino7, Maria Merelli8, Enrico Tagliaferri9, Antonio Corcione10, Matteo Bassetti8, Gianluigi Cardinali3,4, Francesco Menichetti9.   

Abstract

BACKGROUND: Evaluation of the role on patient mortality exerted by biofilm forming (BF) Candida strains, by using predictive clinical data.
METHODS: Eighty-nine strains isolated from Candida bloodstream infection, occurring in two Italian University Hospitals, were employed in this study. A random forest (RF) model was built with a procedure of iterative selection of the risk factors potentially able to predict the probability of death. The similarity between patient conditions and Bayesian clustering was calculated in order to evaluate the role of predictors in the stratification of the death risk.
RESULTS: Three different groups of patients with different probability of death were obtained with a RF approach: Group 1 (mortality in 33.3% of cases), Group 2 (death in 50% of cases), and Group 3 (mortality in 76.9% of cases). The comparison between these three groups showed that BF correlated well with increased mortality in patients, admitted for medical diagnosis, with high APACHE II score and treated with azoles. Early treatment within 24 h between candidemia diagnosis and the beginning of antifungal therapy was associated with the lowest of BF rate and mortality.
CONCLUSIONS: BF by Candida spp. seems to be clinically associated with increased mortality especially in medical patients with higher Apache II score or treated with azoles.

Entities:  

Keywords:  Antifungal therapy; Biofilm; Candidemia

Mesh:

Substances:

Year:  2017        PMID: 28988525     DOI: 10.1080/23744235.2017.1384956

Source DB:  PubMed          Journal:  Infect Dis (Lond)        ISSN: 2374-4243


  11 in total

1.  Rational selection of antifungal drugs to propose a new formulation strategy to control Candida biofilm formation on venous catheters.

Authors:  Paula Reginatto; Vanessa Zafanelli Bergamo; Simone Jacobus Berlitz; Irene Clemes Kulkamp Guerreiro; Saulo Fernandes de Andrade; Alexandre Meneghello Fuentefria
Journal:  Braz J Microbiol       Date:  2020-02-19       Impact factor: 2.476

2.  Ketoconazole resistant Candida albicans is sensitive to a wireless electroceutical wound care dressing.

Authors:  Dolly K Khona; Sashwati Roy; Subhadip Ghatak; Kaixiang Huang; Gargi Jagdale; Lane A Baker; Chandan K Sen
Journal:  Bioelectrochemistry       Date:  2021-08-04       Impact factor: 5.373

3.  Antibiofilm Activity of Essential Fatty Acids Against Candida albicans from Vulvovaginal Candidiasis and Bloodstream Infections.

Authors:  Shuai Wang; Peng Wang; Jun Liu; Chunxia Yang; Qiangyi Wang; Mingze Su; Ming Wei; Li Gu
Journal:  Infect Drug Resist       Date:  2022-08-03       Impact factor: 4.177

4.  Clinical Characteristics and Outcomes of Candidemia Caused by Meyerozyma guilliermondii Complex in Cancer Patients Undergoing Surgery.

Authors:  Jingjing Chen; Sufei Tian; Fushun Li; Guoquan Sun; Ke Yun; Shitong Cheng; Yunzhuo Chu
Journal:  Mycopathologia       Date:  2020-09-28       Impact factor: 2.574

Review 5.  Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation.

Authors:  Siang Fei Yeoh; Tae Jin Lee; Ka Lip Chew; Stephen Lin; Dennis Yeo; Sajita Setia
Journal:  Infect Drug Resist       Date:  2018-05-30       Impact factor: 4.003

6.  In Vitro Anti-Biofilm Activities of Citral and Thymol Against Candida Tropicalis.

Authors:  Apurva Chatrath; Rashmi Gangwar; Poonam Kumari; Ramasare Prasad
Journal:  J Fungi (Basel)       Date:  2019-02-03

7.  Clinical outcome of Escherichia coli bloodstream infection in cancer patients with/without biofilm formation: a single-center retrospective study.

Authors:  Qing Zhang; Hao-Yang Gao; Ding Li; Zheng Li; Shan-Shan Qi; Shan Zheng; Chang-Sen Bai; Si-He Zhang
Journal:  Infect Drug Resist       Date:  2019-02-11       Impact factor: 4.003

Review 8.  Gaining Insights from Candida Biofilm Heterogeneity: One Size Does Not Fit All.

Authors:  Ryan Kean; Christopher Delaney; Ranjith Rajendran; Leighann Sherry; Rebecca Metcalfe; Rachael Thomas; William McLean; Craig Williams; Gordon Ramage
Journal:  J Fungi (Basel)       Date:  2018-01-15

Review 9.  Promising Therapeutic Strategies Against Microbial Biofilm Challenges.

Authors:  Kaiyu Zhang; Xin Li; Chen Yu; Yang Wang
Journal:  Front Cell Infect Microbiol       Date:  2020-07-28       Impact factor: 5.293

10.  Fungicidal Activity of a Safe 1,3,4-Oxadiazole Derivative Against Candida albicans.

Authors:  Daniella Renata Faria; Raquel Cabral Melo; Glaucia Sayuri Arita; Karina Mayumi Sakita; Franciele Abigail Vilugron Rodrigues-Vendramini; Isis Regina Grenier Capoci; Tania Cristina Alexandrino Becker; Patrícia de Souza Bonfim-Mendonça; Maria Sueli Soares Felipe; Terezinha Inez Estivalet Svidzinski; Erika Seki Kioshima
Journal:  Pathogens       Date:  2021-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.